Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
27
NVO Quote, Financials, Valuation and Earnings
Last price:
$48.02
Seasonality move
:
5.86%
Day range:
$47.30 - $48.11
52-week range:
$43.08 - $112.52
Dividend yield:
3.63%
P/E ratio:
13.86x
P/S ratio:
4.54x
P/B ratio:
10.43x
Volume:
11.5M
Avg. volume:
19.9M
1-year change:
-56.44%
Market cap:
$211.4B
Revenue:
$42.1B
EPS (TTM):
$3.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NVO
Novo Nordisk A/S
|
$11.9B | $0.66 | -1.21% | 0.25% | $53.05 |
|
ASND
Ascendis Pharma A/S
|
$245M | -$0.18 | 53.62% | -70.74% | $256.73 |
|
EVAX
Evaxion AS
|
$2.5M | -$0.01 | -100% | -99.68% | $14.18 |
|
OMER
Omeros Corp.
|
-- | -$0.48 | -- | -0.15% | $28.00 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -1.16% | 33.42% | $768.36 |
|
VKTX
Viking Therapeutics, Inc.
|
-- | -$0.67 | -- | -182.02% | $93.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NVO
Novo Nordisk A/S
|
$47.57 | $53.05 | $211.4B | 13.86x | $0.58 | 3.63% | 4.54x |
|
ASND
Ascendis Pharma A/S
|
$200.50 | $256.73 | $12.3B | -- | $0.00 | 0% | 16.77x |
|
EVAX
Evaxion AS
|
$5.10 | $14.18 | $32.2M | -- | $0.00 | 0% | 3.42x |
|
OMER
Omeros Corp.
|
$10.62 | $28.00 | $753M | -- | $0.00 | 0% | -- |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$723.67 | $768.36 | $76.1B | 17.33x | $0.88 | 0.49% | 5.60x |
|
VKTX
Viking Therapeutics, Inc.
|
$35.41 | $93.39 | $4B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NVO
Novo Nordisk A/S
|
37.33% | 1.647 | 6.46% | 0.46x |
|
ASND
Ascendis Pharma A/S
|
127.22% | -0.522 | 7.87% | 0.68x |
|
EVAX
Evaxion AS
|
-- | 5.637 | -- | 2.80x |
|
OMER
Omeros Corp.
|
254.22% | -1.203 | 126.5% | 0.76x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
|
VKTX
Viking Therapeutics, Inc.
|
0.11% | 1.448 | 0.03% | 27.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NVO
Novo Nordisk A/S
|
$8.9B | $3.7B | 41.85% | 68.76% | 31.74% | $4.8B |
|
ASND
Ascendis Pharma A/S
|
$219.4M | $12.9M | -34.4% | -880.05% | 5.15% | $1.3M |
|
EVAX
Evaxion AS
|
-- | -$4.4M | -238.97% | -- | -54.59% | -- |
|
OMER
Omeros Corp.
|
-$240K | -$26.4M | -59.56% | -- | -- | -$18.5M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
VKTX
Viking Therapeutics, Inc.
|
-$114K | -$98.6M | -28.59% | -28.62% | -- | -$94M |
Novo Nordisk A/S vs. Competitors
-
Which has Higher Returns NVO or ASND?
Ascendis Pharma A/S has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of -28.55%. Novo Nordisk A/S's return on equity of 68.76% beat Ascendis Pharma A/S's return on equity of -880.05%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk A/S76.12% $0.70 $42.7B ASNDAscendis Pharma A/S87.87% -$1.17 $751.5M -
What do Analysts Say About NVO or ASND?
Novo Nordisk A/S has a consensus price target of $53.05, signalling upside risk potential of 11.52%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $256.73 which suggests that it could grow by 28.26%. Given that Ascendis Pharma A/S has higher upside potential than Novo Nordisk A/S, analysts believe Ascendis Pharma A/S is more attractive than Novo Nordisk A/S.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk A/S6 3 2 ASNDAscendis Pharma A/S13 0 0 -
Is NVO or ASND More Risky?
Novo Nordisk A/S has a beta of 0.670, which suggesting that the stock is 32.994% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.182%.
-
Which is a Better Dividend Stock NVO or ASND?
Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 3.63%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or ASND?
Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Ascendis Pharma A/S quarterly revenues of $249.6M. Novo Nordisk A/S's net income of $3.1B is higher than Ascendis Pharma A/S's net income of -$71.3M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 13.86x while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.54x versus 16.77x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk A/S4.54x 13.86x $11.7B $3.1B ASNDAscendis Pharma A/S16.77x -- $249.6M -$71.3M
-
Which has Higher Returns NVO or EVAX?
Evaxion AS has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of -64.14%. Novo Nordisk A/S's return on equity of 68.76% beat Evaxion AS's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk A/S76.12% $0.70 $42.7B EVAXEvaxion AS-- -$1.01 $74K -
What do Analysts Say About NVO or EVAX?
Novo Nordisk A/S has a consensus price target of $53.05, signalling upside risk potential of 11.52%. On the other hand Evaxion AS has an analysts' consensus of $14.18 which suggests that it could grow by 177.94%. Given that Evaxion AS has higher upside potential than Novo Nordisk A/S, analysts believe Evaxion AS is more attractive than Novo Nordisk A/S.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk A/S6 3 2 EVAXEvaxion AS2 0 0 -
Is NVO or EVAX More Risky?
Novo Nordisk A/S has a beta of 0.670, which suggesting that the stock is 32.994% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NVO or EVAX?
Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 3.63%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or EVAX?
Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Evaxion AS quarterly revenues of $37.5K. Novo Nordisk A/S's net income of $3.1B is higher than Evaxion AS's net income of -$4.9M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 13.86x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.54x versus 3.42x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk A/S4.54x 13.86x $11.7B $3.1B EVAXEvaxion AS3.42x -- $37.5K -$4.9M
-
Which has Higher Returns NVO or OMER?
Omeros Corp. has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of --. Novo Nordisk A/S's return on equity of 68.76% beat Omeros Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk A/S76.12% $0.70 $42.7B OMEROmeros Corp.-- -$0.47 $143M -
What do Analysts Say About NVO or OMER?
Novo Nordisk A/S has a consensus price target of $53.05, signalling upside risk potential of 11.52%. On the other hand Omeros Corp. has an analysts' consensus of $28.00 which suggests that it could grow by 163.65%. Given that Omeros Corp. has higher upside potential than Novo Nordisk A/S, analysts believe Omeros Corp. is more attractive than Novo Nordisk A/S.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk A/S6 3 2 OMEROmeros Corp.2 2 0 -
Is NVO or OMER More Risky?
Novo Nordisk A/S has a beta of 0.670, which suggesting that the stock is 32.994% less volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.485, suggesting its more volatile than the S&P 500 by 148.518%.
-
Which is a Better Dividend Stock NVO or OMER?
Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 3.63%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or OMER?
Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Omeros Corp. quarterly revenues of --. Novo Nordisk A/S's net income of $3.1B is higher than Omeros Corp.'s net income of -$21.2M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 13.86x while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.54x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk A/S4.54x 13.86x $11.7B $3.1B OMEROmeros Corp.-- -- -- -$21.2M
-
Which has Higher Returns NVO or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of 38.89%. Novo Nordisk A/S's return on equity of 68.76% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk A/S76.12% $0.70 $42.7B REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About NVO or REGN?
Novo Nordisk A/S has a consensus price target of $53.05, signalling upside risk potential of 11.52%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $768.36 which suggests that it could grow by 6.18%. Given that Novo Nordisk A/S has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Novo Nordisk A/S is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk A/S6 3 2 REGNRegeneron Pharmaceuticals, Inc.16 8 0 -
Is NVO or REGN More Risky?
Novo Nordisk A/S has a beta of 0.670, which suggesting that the stock is 32.994% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock NVO or REGN?
Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 3.63%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or REGN?
Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Novo Nordisk A/S's net income of $3.1B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Novo Nordisk A/S's price-to-earnings ratio is 13.86x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.54x versus 5.60x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk A/S4.54x 13.86x $11.7B $3.1B REGNRegeneron Pharmaceuticals, Inc.5.60x 17.33x $3.8B $1.5B
-
Which has Higher Returns NVO or VKTX?
Viking Therapeutics, Inc. has a net margin of 26.68% compared to Novo Nordisk A/S's net margin of --. Novo Nordisk A/S's return on equity of 68.76% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk A/S76.12% $0.70 $42.7B VKTXViking Therapeutics, Inc.-- -$0.81 $713.8M -
What do Analysts Say About NVO or VKTX?
Novo Nordisk A/S has a consensus price target of $53.05, signalling upside risk potential of 11.52%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 163.74%. Given that Viking Therapeutics, Inc. has higher upside potential than Novo Nordisk A/S, analysts believe Viking Therapeutics, Inc. is more attractive than Novo Nordisk A/S.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk A/S6 3 2 VKTXViking Therapeutics, Inc.12 1 0 -
Is NVO or VKTX More Risky?
Novo Nordisk A/S has a beta of 0.670, which suggesting that the stock is 32.994% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.
-
Which is a Better Dividend Stock NVO or VKTX?
Novo Nordisk A/S has a quarterly dividend of $0.58 per share corresponding to a yield of 3.63%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk A/S pays 35.93% of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or VKTX?
Novo Nordisk A/S quarterly revenues are $11.7B, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Novo Nordisk A/S's net income of $3.1B is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Novo Nordisk A/S's price-to-earnings ratio is 13.86x while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk A/S is 4.54x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk A/S4.54x 13.86x $11.7B $3.1B VKTXViking Therapeutics, Inc.-- -- -- -$90.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
65
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
